Heron Therapeutics (HRTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HRTX Heron Therapeutics

Watchlist

1.060
-0.060-5.36%

Close Nov 21 16:00 ET

1.060
0.0000.00%

Post 16:00 ET

161.22MMarket Cap-6625P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

No Data

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsNov 13 09:31 ET · Ratings
Heron Therapeutics (HRTX) Gets a Buy From Northland Securities
TipRanksNov 13 08:56 ET · Ratings
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
BenzingaNov 13 07:45 ET
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Institutional Investors Lost 28% Over the Past Week but Have Profited From Longer-term Gains
Simply Wall StNov 13 05:04 ET
Benign Growth For Heron Therapeutics, Inc. (NASDAQ:HRTX) Underpins Stock's 30% Plummet
Simply Wall StNov 13 05:00 ET
Heron Therapeutics Analyst Ratings
BenzingaNov 13 04:41 ET · Ratings

Comments

Stock_Drift

Oct 10 15:10

$Heron Therapeutics (HRTX.US)$

Jaguar8

Oct 10 15:09

NEWS

$Heron Therapeutics (HRTX.US)$
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

NEWS

$Heron Therapeutics (HRTX.US)$
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time
- The VAN is expected to launch in Q4 2024
SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced tha...